Stock Analysis
Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis
Harmony Biosciences Holdings, Inc. (HRMY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Harmony Biosciences Holdings, Inc. (HRMY) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 89/100. Risk is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
HRMY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $33.76 |
| AIQ Score | 73/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.97B |
| P/E Ratio (TTM) | 10.96 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.83 |
| Revenue (Q3 FY2026) | $268.92M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.63 |
| Volume | 844.9K |
| 52-week range | $25.90-$43.49 |
| RSI 14 | 36.41 |
| 50-Day SMA | $38.65 |
| 200-Day SMA | $34.57 |
| Analyst Price Target | $51.50 |
| Next Earnings | Feb 23, 2027 |
HRMYHarmony Biosciences Holdings, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum66
- Value89
- Quality77
- Risk resilience63
- Sentiment—
HRMY Stock Analysis Summary
Harmony Biosciences Holdings, Inc. (HRMY) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 89/100. Risk resilience is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, HRMY has AIQ Score of 73/100 with Value base of 89/100 and fading Risk resilience at 63/100. Wait for component alignment before adding exposure.
Value (89/100) leads while Risk resilience (63/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.12% stock move · HRMY classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is HRMY Bullish or Bearish Right Now?
HRMY currently has a bullish overall setup. Value is the strongest factor at 89/100, while Risk Resilience is weakest at 63/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 77/100.
- - Momentum is constructive at 66/100.
- - Analyst target implies +52.55% upside from the latest quote.
- - Price is -2.35% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (37 vs 1).
Current Consensus
HRMY's Technical Analysis Consensus is currently Strong Sell, with 1 buy, 8 neutral, and 37 sell votes. HRMY's 14-day RSI is 36.41, which places the stock in a weaker momentum range. HRMY's beta is 0.63, indicating lower market sensitivity than the broad market.
What Changed in HRMY?
The largest recent change in HRMY is Momentum moving down by 8.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the HRMY Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
HRMY Decision Framework
Public evidence layers, setup checks, and risk context for Harmony Biosciences Holdings, Inc..
Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis
Harmony Biosciences Holdings, Inc. has an AIQ Score of 73/100 in a Bullish regime. Value is strongest at 89/100. Beta is 0.63, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | HRMY is in a Bullish AIQ regime with score 73/100. |
| Signal Conflict | The primary conflict is that value leads at 89/100 while risk lags at 63/100. |
| Factor Evidence | Momentum 66/100 · Value 89/100 · Quality 77/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 89/100.
Momentum is 66/100 and RSI (14) is 36.4.
HRMY is in a Bullish regime at 73/100.
Risk factor is 63/100 with beta 0.63 and annual volatility 40.59%.
Current conflict: value leads at 89/100 while risk lags at 63/100.
HRMY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
HRMY Fundamentals
HRMY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
HRMY Technical Analysis
HRMY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
HRMY Stock Catalysts
Track HRMY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
HRMY Dividend Analysis
HRMY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
HRMY Financial Data
HRMY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
HRMY Risk Analysis
HRMY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
HRMY Stock News
HRMY stock news, market tone, recent headlines, and catalyst context.
HRMY vs Biotechnology Peers
Current peer cohort: HRMY · IDYA · IMNM · IMVT · INBX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| HRMY Current stock | 73/100 | 89/100 | 66/100 | 63/100 | 0.07 | 40.59% | Current |
| IDYA IDEAYA Biosciences, Inc. | 54/100 | 39/100 | 63/100 | 61/100 | 0.14 | 44.94% | HRMY vs IDYA |
| IMNM Immunome, Inc. | 48/100 | — | 45/100 | 47/100 | 0.45 | 60.72% | HRMY vs IMNM |
| IMVT Immunovant, Inc. | 52/100 | — | 61/100 | 52/100 | 0.9 | 58.62% | HRMY vs IMVT |
| INBX Inhibrx Biosciences Inc. | 40/100 | — | 50/100 | 40/100 | 0.49 | 82.28% | HRMY vs INBX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for HRMY: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching HRMY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for HRMY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
HRMY Stock FAQ
What is HRMY stock price today?
Harmony Biosciences Holdings, Inc.'s current stock price is $33.76. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is HRMY bullish or bearish right now?
HRMY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is HRMY's market cap?
HRMY's market cap is $1.97B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is HRMY's current P/E ratio?
HRMY's current P/E ratio is 10.96 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is HRMY's RSI?
HRMY's 14-day RSI is 36.41 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is HRMY above its 50-day and 200-day moving averages?
HRMY is -12.65% from its 50-day SMA and -2.35% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is HRMY's next earnings date?
HRMY's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does HRMY pay a dividend?
HRMY's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.